Journals Menu
Follow SCIRP
Contact us
customer@scirp.org
WhatsApp +86 18163351462(WhatsApp)
Click here to send a message to me 1655362766
Paper Publishing WeChat

Journal of Cancer Therapy

Journal of Cancer Therapy

Journal of Cancer Therapy

ISSN Print: 2151-1934
ISSN Online: 2151-1942
www.scirp.org/journal/jct
E-mail: jct@scirp.org
Citations    
"A Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients with Recurrent Glioblastoma Multiforme: Final Report (Protocol BT-21)"
written by Stanislaw R. Burzynski, Tomasz J. Janicki, Gregory S. Burzynski,
published by Journal of Cancer Therapy, Vol.5 No.10, 2014
has been cited by the following article(s):
  • Google Scholar
  • CrossRef
[1] Newly diagnosed Anaplastic Astrocytoma:> 23 Year Survival in a 31-Year and 11-Month-Old Female Treated with Antineoplastons
Neurology and …, 2023
[2] Inoperable Optic Pathway Glioma: A Seven-Year-Old Male with> 35 Years Overall Survival Following Treatment with Antineoplastons
European Journal of …, 2023
[3] Recurrent Medulloblastoma: Complete Response and> than 21 Years and Five Months Overall Survival in a One-Year and Seven-Month-Old Male Treated …
… Review & Reports, 2023
[4] Newly diagnosed Glioblastoma: Partial Response and> 27 Years Overall Survival in a 37-Year-Old Male Treated with Antineoplastons
Recent Adv Clin …, 2022
[5] Newly-Diagnosed Multicentric Pilocytic Astrocytoma: Complete Response and > 23 Years Survival in a Six Year and Nine-Month-Old Female Treated with Antineoplastons
International Journal of Clinical Oncology and Cancer Research, 2022
[6] Outcomes in Four Children with Persistent, Recurrent, and Progressive Gangliogliomas Treated in Phase II Studies with Antineoplastons A10 and AS2-1
Neurology and …, 2022
[7] A 25-year-female with Diffuse Intrinsic Pontine Glioma Surviving for More than Nine Years Following Treatment with Antineoplastons
Cancer …, 2022
[8] Long-term survival (23 years) in a 26-year-old male after Antineoplaston therapy for a progressive, diffuse intrinsic pontine glioma: A case report
Int J Brain Disord …, 2021
[9] Current immunotherapeutic strategies for the treatment of glioblastoma
Chang - Cancers, 2021
[10] Resolution of clinical signs, a complete response, and long-term survival (> 23 Years) in a 3 and ½ month female with a newly diagnosed diffuse intrinsic …
Biomed Res, 2021
[11] Diffuse Intrinsic Pontine Glioma in an 11-Year-Old Female Treated with Antineoplastons: Complete Response and> 25 Years Survival
Pediatrics and …, 2021
[12] Treatment of Recurrent Glioblastoma Multiforme (rGBM) with Antineoplaston AS2-1 in Combination with Targeted Therapy
Cancer and Clinical Oncology, 2019
[13] Primary CNS Tumors and Leptomeningeal, Disseminated and/or Multicentric Disease in Children Treated in Phase II Studies with Antineoplastons A10 …
2016
[14] A Phase II Study of Antineoplastons A10 and AS2-1 in Children with Low-Grade Astrocytomas—Final Report (Protocol BT-13)
2016
[15] Primary CNS Tumors and Leptomeningeal, Disseminated and/or Multicentric Disease in Children Treated in Phase II Studies with Antineoplastons A10 and AS2-1
Cancer and Clinical Oncology, 2016
[16] Primary CNS Tumors and Leptomeningeal, Disseminated and/or Multicentric Disease in Children Treated in Phase II Studies with Antineoplastons A10 and …
2016
[17] Primary CNS tumors and leptomeningeal, disseminated, and/or multicentric disease in children treated in phase II studies with antineoplastons A10 and AS2-1
Cancer Clin Oncol, 2016
[18] A Phase II Study of Antineoplastons A10 and AS2-1 in adult patients with newly-diagnosed anaplastic astrocytoma: Final report (Protocol BT-08)
Cancer & Clinical …, 2015
[19] A phase II study of Antineoplastons A10 and AS2-1 in adult patients with newly-diagnosed anaplastic astrocytoma. Final report (Protocol BT-08)
2015
[20] A Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Newly-Diagnosed Anaplastic Astrocytoma-Final Report (Protocol BT-08)
Cancer and Clinical Oncology, 2015
[21] A Phase II Study of Antineoplastons A10 and AS2-1 in Patients with Brainstem Gliomas. The Report on Non-Diffuse Intrinsic Pontine Glioma (Protocol BT-11)
Journal of Cancer Therapy, 2015
[22] A Phase II Study of Antineoplastons A10 and AS2-1 Injections in Adult Patients With Recurrent Anaplastic Astrocytoma—Final report (Protocol BT-15)
Cancer and Clinical Oncology, 2015
[23] Comprehensive Genomic Profiling of Recurrent Classic Glioblastoma in a Patient Surviving Eleven Years Following Antineoplaston Therapy
Cancer and Clinical Oncology, 2015
[24] Long-Term Survival Over 21 Years and Pathologically Confirmed Complete Response in Pediatric Anaplastic Astrocytoma: A Case Report
J Neurol Stroke, 2015
[25] A Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients with Primary Brain Tumors—Final Report (Protocol BT-09)
Journal of Cancer Therapy, 2015
[26] Recurrent Glioblastoma Multiforme—A Strategy for Long-Term Survival
Journal of Cancer Therapy, 2014
[27] The Effect of Antineoplastons A10 and AS2-1 and Metabolites of Sodium Phenylbutyrate on Gene Expression in Glioblastoma Multiforme
Journal of Cancer Therapy, 2014
[28] Preliminary Findings on the Use of Targeted Therapy in Combination with Sodium Phenylbutyrate in Recurrent Advanced Pancreatic Cancer—A Potential Strategy for Improved Survival
Journal of Cancer Therapy, 2014
[29] Preliminary Findings on the Use of Targeted Therapy in Combination with Sodium Phenylbutyrate in Advanced Malignant Mesothelioma: A Strategy for Improved Survival
Journal of Cancer Therapy, 2014
[30] Preliminary Findings on the Use of Targeted Therapy in Combination with Sodium Phenylbutyrate in Colorectal Cancer after Failure of Second-Line Therapy—A Potential Strategy for Improved Survival
Journal of Cancer Therapy, 2014
[31] A Case of Sustained Objective Response of Recurrent/Progressive Diffuse Intrinsic Pontine Glioma with Phenylbutyrate and Targeted Agents
Journal of Cancer Therapy, 2014
[32] Preliminary Findings on the Use of Targeted Therapy with Pazopanib and Other Agents in Combination with Sodium Phenylbutyrate in the Treatment of Glioblastoma Multiforme
Journal of Cancer Therapy, 2014
[33] Preliminary findings on the use of targeted therapy with pazopanib and other agents in combination with sodium phenylbutyrate in the treatment of …
2014
[34] Preliminary Findings on the Use of Targeted Therapy in Combination with Sodium Phenylbutyrate in Recurrent Advanced Pancreatic Cancer—A Potential …
2014
[35] Recurrent glioblastoma multiforme--A strategy for long-term survival
2014
[36] Preliminary Findings on the Use of Targeted Therapy in Combination with Sodium Phenylbutyrate in Recurrent Advanced Pancreatic Cancer--A Potential …
2014
[37] Preliminary Findings on the Use of Targeted Therapy in Combination with Sodium Phenylbutyrate in Advanced Malignant Mesothelioma: A Strategy for …
2014
[38] Preliminary findings on the use of targeted therapy with pazopanib and other agents in combination with sodium phenylbutyrate in the treatment of glioblastoma …
Journal of Cancer Therapy, 2014
[39] Preliminary findings on the use of targeted therapy in combination with sodium phenylbutyrate in colorectal cancer after failure of second-line therapy—a …
2014
Follow SCIRP
Twitter Facebook Linkedin Weibo
Contact us
customer@scirp.org
WhatsApp +86 18163351462(WhatsApp)
Click here to send a message to me 1655362766
Paper Publishing WeChat
Free SCIRP Newsletters
Copyright © 2006-2025 Scientific Research Publishing Inc. All Rights Reserved.
Top